# Jostein Dahle

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 69 papers | 1,434 citations | 279798<br>23 h-index | 377865<br>34 g-index |
| 69 all docs | 69 docs citations | 69 times ranked | 1371 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma. Scientific Reports, 2022, 12, 6286. | 3.3 | 3 |
| 2 | Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkinâ€™s lymphoma in vitro. PLoS ONE, 2022, 17, e0267543. | 2.5 | 1 |
| 3 | FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphomaâ€”Are We Hitting the Target?. Molecular Imaging and Biology, 2022, 24, 807-817. | 2.6 | 3 |
| 4 | FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1902-1914. | 6.4 | 6 |
| 5 | Myelosuppression in patients treated with<sup>177</sup>Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable. Acta OncolÃ³gica, 2021, 60, 1481-1488. | 1.8 | 5 |
| 6 | The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia, 2020, 34, 1315-1328. | 7.2 | 12 |
| 7 | Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2020, 4, 4091-4101. | 5.2 | 33 |
| 8 | Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkinâ€™s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS ONE, 2020, 15, e0230526. | 2.5 | 22 |
| 9 | <sup>177</sup>Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. Journal of Nuclear Medicine, 2020, 61, 1468-1475. | 5.0 | 9 |
| 10 | Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2311-2321. | 6.4 | 14 |
| 11 | The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. Frontiers in Oncology, 2019, 9, 1301. | 2.8 | 13 |
| 12 | Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1233-1241. | 6.4 | 21 |
| 13 | Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibodyâ€“Radionuclide Conjugate<sup>177</sup>Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2018, 59, 704-710. | 5.0 | 16 |
| 14 | Combination of <sup>177</sup>Luâ€lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of nonâ€Hodgkin's lymphoma. European Journal of Haematology, 2018, 101, 522-531. | 2.2 | 18 |
| 15 | Abstract 848: In vitro and in vivo evaluation of the beta-emitting lutetium-177 labeled anti-CD37 antibody radionuclide conjugate177Lu-NNV003 in DLBCL, CLL and MCL models. , 2018, , . | | 0 |
| 16 | Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). Blood, 2018, 132, 4422-4422. | 1.4 | 3 |
| 17 | Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines. Blood, 2018, 132, 1371-1371. | 1.4 | 0 |
| 18 | Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate <sup>177</sup>Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2017, 58, 48-54. | 5.0 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Red Marrowâ€“Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with <sup>177</sup>Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibodyâ€“Radionuclide Conjugate. Journal of Nuclear Medicine, 2017, 58, 55-61. | 5.0 | 22 |
| 20 | 177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. Blood, 2016, 128, 1780-1780. | 1.4 | 2 |
| 21 | Abstract LB-252: Efficacy and safety results of BetalutinÂ® (177Lu-DOTA-HH1) in a phase I/II study of patients with non-hodgkin B-cell lymphoma (NHL). , 2016, , . | | 0 |
| 22 | Combination of 177lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma. Blood, 2016, 128, 4189-4189. | 1.4 | 0 |
| 23 | The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177lu-Satetraxetan-Lilotomab. Blood, 2016, 128, 5339-5339. | 1.4 | 0 |
| 24 | Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0128816. | 2.5 | 30 |
| 25 | A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. Blood, 2014, 124, 3094-3094. | 1.4 | 3 |
| 26 | 177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice. PLoS ONE, 2014, 9, e103070. | 2.5 | 22 |
| 27 | Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors. Anticancer Research, 2014, 34, 3263-9. | 1.1 | 6 |
| 28 | Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After Î±-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts. International Journal of Radiation Oncology Biology Physics, 2013, 87, 153-159. | 0.8 | 9 |
| 29 | Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. Current Radiopharmaceuticals, 2013, 6, 20-27. | 0.8 | 36 |
| 30 | Comparing High LET <sup>227</sup>Th- and Low LET <sup>177</sup>Lu-trastuzumab in Mice with HER-2 Positive SKBR-3 Xenografts. Current Radiopharmaceuticals, 2013, 6, 78-86. | 0.8 | 13 |
| 31 | Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice. Current Radiopharmaceuticals, 2013, 6, 106-116. | 0.8 | 32 |
| 32 | Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Research, 2013, 33, 85-95. | 1.1 | 35 |
| 33 | Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. Nuclear Medicine Communications, 2012, 33, 838-847. | 1.1 | 28 |
| 34 | Transcriptional responses in irradiated and bystander fibroblasts after low dose Î±-particle radiation. International Journal of Radiation Biology, 2012, 88, 713-719. | 1.8 | 11 |
| 35 | The role of serotonin and p53 status in the radiation-induced bystander effect. International Journal of Radiation Biology, 2012, 88, 773-776. | 1.8 | 22 |
| 36 | A laboratory inter-comparison of the importance of serum serotonin levels in the measurement of a range of radiation-induced bystander effects: Overview of study and results presentation. International Journal of Radiation Biology, 2012, 88, 763-769. | 1.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS ONE, 2012, 7, e42345. | 2.5 | 51 |
| 38 | Genome-Wide Microarray Analysis of Human Fibroblasts in Response to Î³ Radiation and the Radiation-Induced Bystander Effect. Radiation Research, 2011, 177, 35. | 1.5 | 18 |
| 39 | Experimental Î±-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab. EJNMMI Research, 2011, 1, 18. | 2.5 | 47 |
| 40 | Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-Trastuzumab. International Journal of Radiation Oncology Biology Physics, 2011, 79, 563-570. | 0.8 | 35 |
| 41 | Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates. Current Radiopharmaceuticals, 2011, 4, 321-328. | 0.8 | 21 |
| 42 | Dosimetry of a 238Pu-based alpha-particle irradiator and its biological application in a study of the bystander effect. Anticancer Research, 2011, 31, 2113-20. | 1.1 | 9 |
| 43 | Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 93-102. | 6.4 | 35 |
| 44 | In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227â€"DOTAâ€"Rituximab. International Journal of Radiation Oncology Biology Physics, 2009, 75, 886-895. | 0.8 | 20 |
| 45 | A 238Pu irradiator for exposure of cultured cells with alpha-radiation: Construction, calibration and dosimetry. Applied Radiation and Isotopes, 2009, 67, 1998-2002. | 1.5 | 12 |
| 46 | Relative Biologic Effects of Low-Dose-Rate Î±-Emitting 227Th-Rituximab and Î²-Emitting 90Y-Tiuexetan-Ibritumomab Versus External Beam X-Radiation. International Journal of Radiation Oncology Biology Physics, 2008, 72, 186-192. | 0.8 | 36 |
| 47 | Overexpression of human OGG1 in mammalian cells decreases ultraviolet A induced mutagenesis. Cancer Letters, 2008, 267, 18-25. | 7.2 | 22 |
| 48 | Targeted Alpha-Particle Therapy with 227Th-Labeled Antibodies. Current Radiopharmaceuticals, 2008, 1, 209-214. | 0.8 | 16 |
| 49 | Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: An<i>In Vitro</i>Feasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with the<i>Î±</i>-Emitter<sup>227</sup>Th. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 469-479. | 1.0 | 17 |
| 50 | Targeted cancer therapy with a novel low-dose rate Î±-emitting radioimmunoconjugate. Blood, 2007, 110, 2049-2056. | 1.4 | 80 |
| 51 | A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding. Nuclear Medicine Communications, 2007, 28, 742-747. | 1.1 | 1 |
| 52 | Preparation of TH<sup>227</sup>-Labeled Radioimmunoconjugates, Assessment of Serum Stability and Antigen Binding Ability. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 431-437. | 1.0 | 45 |
| 53 | Bystander Effects in Cell Death Induced by Photodynamic Treatment, UVA Radiation and Inhibitors of ATP SynthesisÂ¶. Photochemistry and Photobiology, 2007, 73, 378-387. | 2.5 | 1 |
| 54 | Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate Î±-particle radioimmunotherapy. Nuclear Medicine and Biology, 2006, 33, 271-279. | 0.6 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Bystander effects in UV-induced genomic instability: antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation. Journal of Carcinogenesis, 2005, 4, 11. | 2.5 | 65 |
| 56 | Bystander Effects may Modulate Ultraviolet A and B Radiation-Induced Delayed Mutagenesis. Radiation Research, 2005, 163, 289-295. | 1.5 | 24 |
| 57 | The pheomelanin precursor 5-S-cysteinyldopa protects melanocytes from membrane damage induced by ultraviolet A radiation. Cancer Letters, 2005, 221, 131-134. | 7.2 | 5 |
| 58 | Multiplex Polymerase Chain Reaction Analysis of UVâ€Aâ€“ and UVâ€Bâ€“induced Delayed and Early Mutations in V79 Chinese Hamster Cells<sup>Â¶</sup>. Photochemistry and Photobiology, 2005, 81, 114-119. | 2.5 | 0 |
| 59 | Multiplex Polymerase Chain Reaction Analysis of UV-Aâ€“ and UV-Bâ€“induced Delayed and Early Mutations in V79 Chinese Hamster CellsÂ¶. Photochemistry and Photobiology, 2005, 81, 114. | 2.5 | 9 |
| 60 | Melanin Synthesis may Sensitize Melanocytes to Oxidative DNA Damage by Ultraviolet A Radiation and Protect Melanocytes from Direct DNA Damage by Ultraviolet B Radiation. Pigment Cell & Melanoma Research, 2004, 17, 549-550. | 3.6 | 19 |
| 61 | Automated counting of mammalian cell colonies by means of a flat bed scanner and image processing. Cytometry, 2004, 60A, 182-188. | 1.8 | 55 |
| 62 | Increased level of oxidative stress in genomically unstable cell clones. Journal of Photochemistry and Photobiology B: Biology, 2004, 74, 23-28. | 3.8 | 8 |
| 63 | Pigmented Melanocytes Are Protected Against Ultraviolet-A-Induced Membrane Damage. Journal of Investigative Dermatology, 2003, 121, 564-569. | 0.7 | 34 |
| 64 | Induction of delayed mutations and chromosomal instability in fibroblasts after UVA-, UVB-, and X-radiation. Cancer Research, 2003, 63, 1464-9. | 0.9 | 79 |
| 65 | Bystander Effects in Cell Death Induced by Photodynamic Treatment, UVA Radiation and Inhibitors of ATP SynthesisÂ¶. Photochemistry and Photobiology, 2001, 73, 378. | 2.5 | 29 |
| 66 | Gap Junctional Intercellular Communication is not a Major Mediator in the Bystander Effect in Photodynamic Treatment of MDCK II Cells. Radiation Research, 2000, 154, 331-341. | 1.5 | 26 |
| 67 | The Mode of Cell Death Induced by Photodynamic Treatment Depends on Cell Density. Photochemistry and Photobiology, 1999, 70, 363-367. | 2.5 | 58 |
| 68 | Cooperative Inactivation of Cells in Microcolonies Treated with UVA Radiation. Radiation Research, 1999, 152, 174. | 1.5 | 14 |
| 69 | <title>Cooperative effects of photosensitized cell killing</title>. , 1999, , . | | 0 |